Arrowstreet Capital
MYGN icon

Arrowstreet Capital’s Myriad Genetics MYGN Stock Holding History

Arrowstreet Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$921K Buy
+204,608
New +$1.07M ﹤0.01% 1571
2025
Q1 		– Sell
-153,062
Closed -$2.1M – 1941
2024
Q4 		$2.1M Sell
153,062
-24,519
-14% -$452K ﹤0.01% 1265
2024
Q3 		$4.86M Buy
+177,581
New +$4.81M ﹤0.01% 966
2021
Q1 		– Sell
-18,264
Closed -$361K – 2426
2020
Q4 		$361K Sell
18,264
-515,954
-97% -$8.33M ﹤0.01% 2082
2020
Q3 		$6.97M Sell
534,218
-308,782
-37% -$3.91M 0.01% 995
2020
Q2 		$9.56M Buy
+843,000
New +$12M 0.02% 791
2020
Q1 		– Sell
-22,900
Closed -$624K – 2022
2019
Q4 		$624K Buy
+22,900
New +$630K ﹤0.01% 1449
2018
Q4 		– Sell
-114,429
Closed -$5.26M – 1447
2018
Q3 		$5.26M Buy
114,429
+98,429
+615% +$4.38M 0.01% 500
2018
Q2 		$598K Sell
16,000
-12,248
-43% -$414K ﹤0.01% 887
2018
Q1 		$835K Sell
28,248
-29,252
-51% -$990K ﹤0.01% 897
2017
Q4 		$1.98M Buy
+57,500
New +$1.94M ﹤0.01% 824
2016
Q2 		– Sell
-49,657
Closed -$1.86M – 1443
2016
Q1 		$1.86M Buy
+49,657
New +$1.87M 0.01% 836
2015
Q3 		– Sell
-66,829
Closed -$2.27M – 1443
2015
Q2 		$2.27M Buy
+66,829
New +$2.27M 0.01% 606
2014
Q1 		– Sell
-166,872
Closed -$3.5M – 1261
2013
Q4 		$3.5M Sell
166,872
-17,307
-9% -$438K 0.02% 530
2013
Q3 		$4.33M Buy
184,179
+102,430
+125% +$2.91M 0.03% 406
2013
Q2 		$2.2M Buy
+81,749
New +$2.37M 0.02% 443

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital's MYGN Position: Q1 2026 in Review

Arrowstreet Capital opened a new position in Myriad Genetics (MYGN) in Q1 2026: 204,608 shares worth $921K. The stake represents ﹤0.01% of the portfolio and ranks #1571 among its holdings. This is a return to the name: Arrowstreet Capital previously reported a position in MYGN as recently as Q4 2024.

Arrowstreet Capital first reported a position in MYGN in Q2 2013 and has held it in 16 quarters since. The position peaked at $9.56M in Q2 2020. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Arrowstreet Capital held 204,608 shares of Myriad Genetics worth $921K as of Q1 2026.
  • Myriad Genetics was a new Arrowstreet Capital position in Q1 2026.
  • Myriad Genetics made up ﹤0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #1571 holding.
  • Arrowstreet Capital first reported a position in Myriad Genetics in Q2 2013 and has held it in 16 quarters since.
  • Arrowstreet Capital's Myriad Genetics position peaked at $9.56M in Q2 2020.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.